The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Open accessAbstract
IMPORTANCE: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE: To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).16”
From Type 1 diabetes (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most individuals without diabetes who have only one autoantibody will not develop type 1 diabetes, as the 10-year risk is about 15% (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a nearcertain predictor of clinical diabetes (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a near-certain predictor of clinical diabetes (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A seminal analysis of four different birth cohorts from the USA, Finland and Germany demonstrated that the presence of a single islet autoantibody is associated with a 13% risk of developing type 1 diabetes over 15 years. In contrast, having two or more antibodies is associated with a 70% risk over 10 years of observation and an 84% risk over 15 years63.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, studies of the offspring of people with diabetes show that young children with multiple autoantibodies develop diabetes during childhood [ 12 ]”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“In children with only one persistent islet autoantibody, the risk of diabetes within 10 years is 15% while two or more islet autoantibodies predict type 1 diabetes in 70% within 10 years (408,409).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Self-citationGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Self-citationQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes
Bonifacio, E. E., Shattock, M., Dean, B. M., Bottazzo, G. F., Bingley, P. J., Gale, E., & Dunger, D. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)90013-u · Cited by 344
Self-citationStratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E. E., & Ziegler, A. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 276
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationPREDICTING INSULIN-DEPENDENT DIABETES
Tarn, A., Dean, B., Schwarz, G., Thomas, J. M., Ingram, D., Bottazzo, G. F., & Gale, E. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91601-7 · Cited by 260
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,001
Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes
McLaughlin, K. A., Richardson, C. C., Ravishankar, A., Brigatti, C., Liberati, D., Lampasona, V., Piemonti, L., Morgan, D., Feltbower, R. G., & Christie, M. R. (2016) · Diabetes · doi:10.2337/db15-1058 · Cited by 113
Viisanen, T., Ihantola, E., Näntö‐Salonen, K., Hyöty, H., Nurminen, N., Selvenius, J., Juutilainen, A., Moilanen, L., Pihlajamäki, J., Veijola, R., et al. (2016) · Diabetes · doi:10.2337/db16-0714 · Cited by 113
Self-citationPreclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities
Torres, J., Burisch, J. M., Riddle, M. S., Dubinsky, M. C., & Colombel, J. (2016) · Gut · doi:10.1136/gutjnl-2016-311785 · Cited by 117
Prediction and Prevention of Type 1 Diabetes
Primavera, M., Giannini, C., & Chiarelli, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00248 · Cited by 130
Lampasona, V., & Liberati, D. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0738-2 · Cited by 111
Hippich, M., Holthaus, L., Assfalg, R., Zapardiel‐Gonzalo, J., Kapfelsperger, H., Heigermoser, M., Haupt, F., Ewald, D., Welzhofer, T., Marcus, B. A., et al. (2020) · Med · doi:10.1016/j.medj.2020.10.003 · Cited by 111
Self-citationCalvo, T. R., Zapardiel‐Gonzalo, J., Amirian, N., Castillo, E., Lajevardi, Y., Krogvold, L., Dahl‐Jørgensen, K., & von Herrath, M. G. (2017) · Diabetes · doi:10.2337/db16-1343 · Cited by 112
Rak, K., & Bronkowska, M. (2018) · Molecules · doi:10.3390/molecules24010053 · Cited by 114
Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study
Vehik, K., Lynch, K. F., Schatz, D. A., Akolkar, B., Hagopian, W., Rewers, M., She, J.-X., Simell, O., Toppari, J., Ziegler, A.-G., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0181 · Cited by 103
Self-citationEkman, I., Ihantola, E., Viisanen, T., Rao, D. A., Näntö‐Salonen, K., Knip, M., Veijola, R., Toppari, J., Ilonen, J., & Kinnunen, T. T. (2019) · Diabetologia · doi:10.1007/s00125-019-4936-8 · Cited by 103
Self-citationCare of diabetes in children and adolescents: controversies, changes, and consensus
Cameron, F. J., & Wherrett, D. K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60971-0 · Cited by 99
Preventing type 1 diabetes in childhood
Dayan, C. M., Besser, R. E. J., Oram, R. A., Hagopian, W., Vatish, M., Bendor-Samuel, O., Snape, M. D., & Todd, J. A. (2021) · Science · doi:10.1126/science.abi4742 · Cited by 102
Steck, A. K., Dong, F., Rasmussen, C. G., BAUTISTA, K. A., Sepulveda, F., Baxter, J., Yu, L., Frohnert, B. I., & Rewers, M. (2021) · Diabetes Care · doi:10.2337/dc21-0602 · Cited by 105
Self-citationKynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?
Kozieł, K., & Urbańska, E. M. (2023) · Cells · doi:10.3390/cells12030460 · Cited by 104
A1 beta-casein milk protein and other environmental pre-disposing factors for type 1 diabetes
Chia, J. S., McRae, J. L., Kukuljan, S., Woodford, K. B., Elliott, R. B., Swinburn, B. A., & Dwyer, K. M. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.16 · Cited by 100
Miao, D., Guyer, K. M., Dong, F., Jiang, L., Steck, A. K., Rewers, M., Eisenbarth, G. S., & Yu, L. (2013) · Diabetes · doi:10.2337/db13-0534 · Cited by 97
Self-citationPenno, M. A. S., Couper, J., Craig, M. E., Colman, P. G., Rawlinson, W. D., Cotterill, A. M., Jones, T. W., Harrison, L. C., & ENDIA Study Group (2013) · BMC Pediatrics · doi:10.1186/1471-2431-13-124 · Cited by 95
Lamichhane, S., Ahonen, L. L., Dyrlund, T. S., Kemppainen, E., Siljander, H., Hyöty, H., Ilonen, J., Toppari, J., Veijola, R., Hyötyläinen, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28907-8 · Cited by 94
Self-citationThe MHC-II peptidome of pancreatic islets identifies key features of autoimmune peptides
Wan, X., Vomund, A. N., Peterson, O. J., Chervonsky, A. V., Lichti, C. F., & Unanue, E. R. (2020) · Nature Immunology · doi:10.1038/s41590-020-0623-7 · Cited by 96
A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes
Girdhar, K., Huang, Q., Chow, I., Vatanen, T., Brady, C., Raisingani, A., Autissier, P., Atkinson, M. A., Kwok, W. W., Kahn, C. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120028119 · Cited by 103
Insulitis in the pathogenesis of type 1 diabetes
Pugliese, A. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12388 · Cited by 101
Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1429 · Cited by 96
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Krupa, A., & Kowalska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189879 · Cited by 93
Sebastiani, G., Nigi, L., Grieco, G. E., Mancarella, F., Ventriglia, G., & Dotta, F. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0611-4 · Cited by 87
Ziegler, A., Achenbach, P., Berner, R., Casteels, K., Danne, T., Gündert, M., Hasford, J., Hoffmann, V. S., Kordonouri, O., Lange, K., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028578 · Cited by 78
Self-citationThe IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation
Bayer, A. L., Pugliese, A., & Malek, T. R. (2013) · Immunologic Research · doi:10.1007/s12026-013-8452-5 · Cited by 89
Vehik, K., Bonifacio, E., Lernmark, Å., Yu, L., Williams, A., Schatz, D., Rewers, M., She, J.-X., Toppari, J., Hagopian, W., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2547 · Cited by 87
Self-citationIslet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes
Giannopoulou, E. Z., Winkler, C., Chmiel, R., Matzke, C., Scholz, M., Beyerlein, A., Achenbach, P., Bonifacio, E. E., & Ziegler, A. (2015) · Diabetologia · doi:10.1007/s00125-015-3672-y · Cited by 87
Self-citationFrommer, L., & Kahaly, G. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00602 · Cited by 86
HbA1c Predicts Time to Diagnosis of Type 1 Diabetes in Children at Risk
Helminen, O., Aspholm, S., Pokka, T. M.-L., Hautakangas, M., Haatanen, N., Lempainen, J., Ilonen, J., Simell, O., Knip, M., & Veijola, R. (2014) · Diabetes · doi:10.2337/db14-0497 · Cited by 89
Self-citationThe Role of Epigenetics in Type 1 Diabetes
Jerram, S. T., Dang, M. N., & Leslie, R. D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0916-x · Cited by 86
Innate inflammation in type 1 diabetes
Cabrera, S. M., Henschel, A. M., & Hessner, M. J. (2015) · Translational research · doi:10.1016/j.trsl.2015.04.011 · Cited by 87
Perry, D. J., Wasserfall, C., Oram, R., Williams, M. D., Posgai, A., Muir, A. B., Haller, M., Schatz, D., Wallet, M., Mathews, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22574-5 · Cited by 73
Anand, V., Li, Y., Liu, B., Ghalwash, M., Koski, E., Ng, K., Dunne, J. L., Jönsson, J., Winkler, C., Knip, M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1836 · Cited by 83
Self-citationBingley, P. J., Wherrett, D. K., Shultz, A., Rafkin, L. E., Atkinson, M. A., & Greenbaum, C. J. (2018) · Diabetes Care · doi:10.2337/dc17-0806 · Cited by 87
Michels, A. W., Zhang, L., Khadra, A., Kushner, J. A., REDONDO, M. J., & Pietropaolo, M. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12299 · Cited by 87
Impact of hyperglycemia on immune cell function: a comprehensive review
Lee, H., Kim, M.-J., Lee, I.-K., Hong, C.-W., & Jeon, J. (2024) · Diabetology International · doi:10.1007/s13340-024-00741-6 · Cited by 95
Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality
Quinn, L. M., Wong, F. S., & Narendran, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737964 · Cited by 90
Utility of genetic risk scores in type 1 diabetes
Luckett, A. M., Weedon, M. N., Hawkes, G., Leslie, R. D., Oram, R. A., & Grant, S. F. A. (2023) · Diabetologia · doi:10.1007/s00125-023-05955-y · Cited by 80
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0042 · Cited by 79
Self-citationImmunological biomarkers for the development and progression of type 1 diabetes
Mathieu, C., Lahesmaa, R., Bonifacio, E. E., Achenbach, P., & Tree, T. I. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4726-8 · Cited by 82
Self-citationLernmark, Å., & Alshiekh, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.15001-5 · Cited by 79
miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes
Scherm, M. G., Serr, I., Zahm, A. M., Schug, J., Bellusci, S., Manfredini, R., Salb, V. K., Gerlach, K., Weigmann, B., Ziegler, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13587-3 · Cited by 81
Self-citationKrischer, J. P., Liu, X., Lernmark, Å., Hagopian, W., Rewers, M., She, J., Toppari, J., Ziegler, A., Akolkar, B., TEDDY Study Group, et al. (2022) · Diabetes Care · doi:10.2337/dc21-2612 · Cited by 77
Self-citationSnowhite, I. V., Allende, G., Sosenko, J. M., Pastori, R. L., Messinger, S., & Pugliese, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4294-3 · Cited by 78
Phases of type 1 diabetes in children and adolescents
Couper, J., Haller, M. J., Ziegler, A., Knip, M., Ludvigsson, J., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12188 · Cited by 81
Self-citationWeiß, A., Zapardiel‐Gonzalo, J., Voss, F., Jolink, M., Stock, J., Haupt, F., Kick, K., Welzhofer, T., Heublein, A., Winkler, C., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05780-9 · Cited by 79
Self-citationAdvances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count
So, M., Speake, C., Steck, A. K., Lundgren, M., Colman, P. G., Palmer, J. P., Herold, K. C., & Greenbaum, C. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab013 · Cited by 75
Self-citationNakayama, M., McDaniel, K. A., Fitzgerald-Miller, L., Kiekhaefer, C. M., Snell‐Bergeon, J. K., Davidson, H. W., Rewers, M., Yu, L., Gottlieb, P. A., Kappler, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502967112 · Cited by 73
Self-citationSerum biomarkers for diagnosis and prediction of type 1 diabetes
Yi, L., Swensen, A., & Qian, W. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.009 · Cited by 80
Antvorskov, J. C., Halldorsson, T. I., Josefsen, K. E., Svensson, J., Granström, C., Roep, B. O., Olesen, T. H., Hrólfsdóttir, L., Buschard, K., & Olsen, S. F. (2018) · BMJ · doi:10.1136/bmj.k3547 · Cited by 73
the Type 1 Diabetes TrialNet Study Group, Bingley, P. J., Boulware, D. C., & Krischer, J. P. (2015) · Diabetologia · doi:10.1007/s00125-015-3830-2 · Cited by 72
A divergent population of autoantigen-responsive CD4+T cells in infants prior to β cell autoimmunity
Heninger, A., Eugster, A., Kuehn, D., Buettner, F., Kühn, M., Lindner, A., Dietz, S., Jergens, S., Wilhelm, C., Beyerlein, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8848 · Cited by 73
Self-citationWood-Heickman, L. K., DeBoer, M., & Fasano, A. (2020) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.3309 · Cited by 65
Circular RNAs in diabetes mellitus and its complications
Fan, W., Pang, H., Xie, Z., Huang, G., & Zhou, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.885650 · Cited by 84
Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E. E., Colhoun, H. M., Couper, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06205-5 · Cited by 83
Self-citationT cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review
Gomez-Touriño, I. M., Arif, S., Eichmann, M., & Peakman, M. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.012 · Cited by 73
Emerging Roles of Exosomes in T1DM
Pang, H., Luo, S., Xiao, Y., Xia, Y., Li, X., Huang, G., Xie, Z., & Zhou, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593348 · Cited by 70
The Genetic Architecture of Type 1 Diabetes
Jerram, S. T., & Leslie, R. D. (2017) · Genes · doi:10.3390/genes8080209 · Cited by 80
Pugliese, A., Boulware, D., Yu, L., Babu, S., Steck, A. K., Becker, D., Rodriguez, H., DiMeglio, L., Evans-Molina, C., Harrison, L. C., et al. (2016) · Diabetes · doi:10.2337/db15-1105 · Cited by 68
Self-citationHarmonization of immunoassays for biomarkers in diabetes mellitus
Hörber, S., Achenbach, P., Schleicher, E. D., & Peter, A. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.015 · Cited by 77
Raab, J., Giannopoulou, E. Z., Schneider, S., Warncke, K., Krasmann, M., Winkler, C., & Ziegler, A. (2014) · Diabetologia · doi:10.1007/s00125-014-3181-4 · Cited by 67
Self-citationZiegler, A., Danne, T., Dunger, D. B., Berner, R., Puff, R., Kiess, W., Agiostratidou, G., Todd, J., & Bonifacio, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.02.003 · Cited by 62
Self-citationGorus, F., Balti, E. V., Messaaoui, A., Demeester, S., Dalem, A. V., Costa, O. R., Dorchy, H., Mathieu, C., Gaal, L. V., Keymeulen, B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2228 · Cited by 67
Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents
Ferrara-Cook, C. T., Geyer, S. M., Evans‐Molina, C., Libman, I. M., BECKER, D. J., Gitelman, S. E., REDONDO, M. J., & the Type 1 Diabetes TrialNet Study Group (2020) · Diabetes Care · doi:10.2337/dc19-1167 · Cited by 67
Proinsulin C-peptide is an autoantigen in people with type 1 diabetes
So, M., Elso, C. M., Tresoldi, E., Pakusch, M., Pathiraja, V., Wentworth, J. M., Harrison, L. C., Krishnamurthy, B., Thomas, H. E., Rodda, C. P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809208115 · Cited by 69
The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes
Purcell, A. W., Sechi, S., & DiLorenzo, T. P. (2019) · Diabetes · doi:10.2337/dbi18-0066 · Cited by 65
Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years
Pöllänen, P. M., Ryhänen, S. J., Toppari, J., Ilonen, J., Vähäsalo, P., Veijola, R., Siljander, H., & Knip, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa624 · Cited by 64
Self-citationTwo-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study
Ghalwash, M. F., Dunne, J. L., Lundgren, M., Rewers, M., Ziegler, A., Anand, V., Toppari, J., Veijola, R., & Hagopian, W. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00141-3 · Cited by 69
Self-citationPrecision medicine in type 1 diabetes
Carr, A. L. J., Evans‐Molina, C., & Oram, R. A. (2022) · Diabetologia · doi:10.1007/s00125-022-05778-3 · Cited by 69
Miao, D., Steck, A. K., Zhang, L., Guyer, K. M., Jiang, L., Armstrong, T., Muller, S. M., Krischer, J. P., Rewers, M., Yu, L., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0186 · Cited by 64
Self-citationBosi, E., Boulware, D. C., Becker, D. J., Buckner, J. H., Geyer, S. M., Gottlieb, P. A., Henderson, C., Kinderman, A., Sosenko, J. M., Steck, A. K., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00569 · Cited by 67
Self-citationViisanen, T., Gazali, A. M., Ihantola, E., Ekman, I., Näntö‐Salonen, K., Veijola, R., Toppari, J., Knip, M., Ilonen, J., & Kinnunen, T. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00019 · Cited by 64
Self-citationAntigen Presentation in the Autoimmune Diabetes of the NOD Mouse
Unanue, E. R. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095941 · Cited by 63
Ilonen, J., Lempainen, J., Hammais, A., Laine, A., Härkönen, T., Toppari, J., Veijola, R., Knip, M., & Register, T. F. P. D. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12545 · Cited by 63
Self-citationThe β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 75
Ward, Z. J., Yeh, J. M., Reddy, C. L., Gomber, A., Ross, C., Rittiphairoj, T., Manne‐Goehler, J., Abdalla, A. T., Abdullah, M. A., Ahmed, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00276-5 · Cited by 63
Kinin receptors: Key regulators of autoimmunity
Dutra, R. C. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.12.011 · Cited by 66
Larsson, H. E., Lundgren, M., Jónsdóttir, B., Cuthbertson, D. D., Krischer, J. P., & for the DiAPREV‐IT Study Group (2017) · Pediatric Diabetes · doi:10.1111/pedi.12611 · Cited by 63
A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes
Serr, I., Scherm, M. G., Zahm, A. M., Schug, J., Flynn, V. K., Hippich, M., Kälin, S., Becker, M., Achenbach, P., Nikolaev, A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1782 · Cited by 63
Self-citationPandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study
Ruiz, P. L., Tapia, G., Bakken, I. J., Håberg, S. E., Hungnes, O., Gulseth, H. L., & Stene, L. C. (2018) · Diabetologia · doi:10.1007/s00125-018-4662-7 · Cited by 63
Kallionpää, H., Somani, J., Tuomela, S., Ullah, U., de Albuquerque, R., Lönnberg, T., Komsi, E., Siljander, H., Honkanen, J. K., Härkönen, T., et al. (2019) · Diabetes · doi:10.2337/db19-0287 · Cited by 66
Self-citationOral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
Assfalg, R., Knoop, J., Hoffman, K. L., Pfirrmann, M., Zapardiel‐Gonzalo, J., Hofelich, A., Eugster, A., Weigelt, M., Matzke, C., Reinhardt, J., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05376-1 · Cited by 68
Self-citationBlood-based signatures in type 1 diabetes
Cabrera, S. M., Chen, Y.-G., Hagopian, W., & Hessner, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3843-x · Cited by 63
Winkler, C., Haupt, F., Heigermoser, M., Zapardiel‐Gonzalo, J., Ohli, J., Faure, T., Kalideri, E., Hommel, A., Delivani, P., Berner, R., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12870 · Cited by 63
Self-citationVendrame, F., Hopfner, Y.-Y., Diamantopoulos, S., Virdi, S. K., Allende, G., Snowhite, I. V., Reijonen, H., Chen, L., Ruiz, P., Ciancio, G., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13426 · Cited by 63
Role of Viruses and Other Microbes in the Pathogenesis of Type 1 Diabetes
Kondrashova, A., & Hyöty, H. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.889130 · Cited by 68
Shi, D., Ran, M., Zhang, L., Huang, H., Li, X., Chen, M., & Akashi, M. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b02121 · Cited by 62
Doliba, N. M., Rozo, A. V., Roman, J., Qin, W. D., Traum, D., Gao, L., Liu, J., Manduchi, E., Liu, C., Golson, M. L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156243 · Cited by 63
Lessons From Pancreas Transplantation in Type 1 Diabetes: Recurrence of Islet Autoimmunity
Burke, G. W., Vendrame, F., Virdi, S. K., Ciancio, G., Chen, L., Ruiz, P., Messinger, S., Reijonen, H., & Pugliese, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0691-5 · Cited by 62
Lempainen, J., Laine, A., Hammais, A., Toppari, J., Simell, O., Veijola, R., Knip, M., & Ilonen, J. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.05.005 · Cited by 62
Self-citationLarsson, H. E., Vehik, K., Haller, M. J., Liu, X., Akolkar, B., Hagopian, W., Krischer, J. P., Lernmark, Å., She, J., Simell, O., et al. (2016) · Diabetes · doi:10.2337/db15-1180 · Cited by 62
Self-citationThe Changing Epidemiology of Type 1 Diabetes: A Global Perspective
Bell, K. J., & Lain, S. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16501 · Cited by 61
Moulder, R., Bhosale, S. D., Erkkilä, T., Laajala, E., Salmi, J., Nguyen, E. V., Kallionpää, H., Mykkänen, J., Vähä-Mäkilä, M., Hyöty, H., et al. (2015) · Diabetes · doi:10.2337/db14-0983 · Cited by 59
Self-citationIntroduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 59
Serr, I., Fürst, R. W., Ott, V. B., Scherm, M. G., Nikolaev, A., Gökmen, F., Kälin, S., Zillmer, S., Bunk, M., Weigmann, B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606646113 · Cited by 58
Self-citationPathways governing development of stem cell‐derived pancreatic β cells: lessons from embryogenesis
Al‐Khawaga, S., Memon, B., Butler, A. E., Taheri, S., Abou‐Samra, A., & Abdelalim, E. M. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12349 · Cited by 59
Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment
Newby, B. N., & Mathews, C. E. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00232 · Cited by 57
Birth and coming of age of islet autoantibodies
Bonifacio, E. E., & Achenbach, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13360 · Cited by 60
Self-citation
Metadata
- Authors
- Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., Bonifacio, E., & Eisenbarth, G. S.
- Affiliations
- TUM Klinikum (DE)
- University of Helsinki (FI)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-19
- Volume
- 309
- Issue
- 23
- Pages
- 2473
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4878912
- OpenAlex
- W2095256598
- Semantic Scholar
- 5a7a8cb24a1d4a727e23b19c717a8328b3ce09d6
- Cited by
- 1,312
- References
- 29
- Citations by year
- 2026: 118 · 2025: 133 · 2024: 103 · 2023: 124 · 2022: 107 · 2021: 127 · 2020: 83 · 2019: 92 · 2018: 92 · 2017: 86 · 2016: 89 · 2015: 83 · 2014: 55 · 2013: 18
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Juvenile Diabetes Research Foundation International (4‐1999‐731, 4‐2001‐435)
- Deutsche Forschungsgemeinschaft (/14-2, /14-1)
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Lastentautien Tutkimussäätiö
- National Institutes of Health (DK32493)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK32493, R01DK032493, U01DK063821)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, seroconversion, multiple autoantibodies, progression to diabetes, insulin autoantibodies, GAD65 antibodies, IA-2 autoantibodies, preclinical diabetes, risk prediction, age at seroconversion, islet transplantation
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Diabetes Mellitus, Type 1, Female, Finland, Follow-Up Studies, Genotype, Germany, Glutamate Decarboxylase, Humans, Infant, Insulin, Islets of Langerhans, Male, Prospective Studies, Risk, Disease Progression, Genetic Predisposition to Disease, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
